Dublin, March 06, 2017 -- Research and Markets has announced the addition of the "Next Generation Sequencing Markets (Systems, Consumables, Services, Competitive Analysis, Trends, Platforms)" report to their offering.
This report, Next Generation Sequencing Markets (Systems, Consumables, Services, Competitive Analysis, Trends, Platforms) covers the market for NGS including a market estimate and a projection to 2020, regional growth for North America, Europe and Other regions, markets by disease category and instrument popularity from lab self reporting surveys.
The report also covers investments in sequencing, trends and detail about manufacturers and service companies in NGS.
A unique feature of this report is its focus on the interplay between in vitro diagnostics (IVD) and sequencing, with detailedexamples of diagnostic companies and clinical laboratories that have made agreements in next generation sequencing. Illumina, Thermo Fisher and other companies are analyzed in the report.
Key Topics Covered:
Chapter 1: Executive Summary
- Overview
- Scope and Methodology
- Market Overview
- Future Prospects in the Sequencing Market
Chapter 2: Introduction
- Overview - Next Generation Sequencing Market Is Rapidly Changing
- History of DNA Sequencing
- Point-of-View
Chapter 3: Sequencing Technology
- Sanger Sequencing
- Next-Generation Sequencing
- Massively Parallel Signature Sequencing (MPSS)
- Pyrosequencing
- 454 Technology
- Sequencing by Synthesis (SBS)
- Supported Oligonucleotide Ligation and Detection (SOLiD)
- Ion Torrent Sequencing
- Single Molecule Real Time (SMRT) Sequencing
- DNA Nano Ball Sequencing
- Nanopore Sequencing
- Other Sequencing Technologies
- Sequencing Applications/Types of Sequencing
- Sample or Library Preparation
- Information Technology
- Sample-to-Answer (Sample-to-Insight) Workflows or Platforms
- Rapid Next Generation Sequencing Testing
Chapter 4: Sequencing Applications
- Research, Drug Discovery and Development
- Clinical Diagnostic Applications of Sequencing
- Cancer Diagnostics: NGS Based Tests for Oncology
- Cancer Diagnostics: Liquid Biopsies
- Genetic Analysis - Inherited Disorders, Prenatal and Postnatal Diagnostics
- Infectious Disease Diagnostics
- Human Leukocyte Antigen (HLA) Testing
- Other Diagnostic Applications of Sequencing
- Direct-to-Consumer Genetic Testing Industry
Chapter 5: Deals - Next Generation Sequencing Companies
- Investments and Financing Agreements
- Mergers and Acquisitions
- Other Corporate Agreements and Collaborations
- Collaborations/Agreements with Diagnostic Companies and/or Clinical Laboratories
- Collaborations/Agreements with Pharmaceutical and Biopharmaceutical Companies
- Collaborations/Agreements between Two Companies in Next Generation Sequencing
- Other Company Collaborations/Agreements
- Collaborations and Other Agreements with Universities, Non-Profit Research Institutes and Government
Chapter 6: Applying Sequencing to Diagnostics - Market Drivers and Challenges
- Overcoming Technology Hurdles - Sample Preparation and Data Analysis
- Advances in Next Generation Sequencing Platforms
- Next Generation Sequencing Market Drivers
- Advances in Technology
- Research Market Drivers
- Increasing Number of Clinical Applications for Next Generation Sequencing
- Cancer Diagnostic Market Drivers
- Genetic Analysis [Inherited Disorders, Prenatal and Postnatal Diagnostics] Market Drivers
- Infectious Disease Diagnostic Market Drivers
- Market Drivers for Other Segments of the Diagnostic Market
- Issues and Hurdles Faced by NGS Companies Selling to the Research Market
- Issues and Hurdles Faced by Clinical Laboratories Doing NGS
- Regulation of Next Generation Sequencing-Based In Vitro Diagnostic (IVD) Tests
- Regulation of Companion Diagnostics
- Complexities of Companion Diagnostic Tests and Corresponding Therapeutic Products; Harmonization of Companion Diagnostic Tests Across a Class of Targeted Therapies
- Cost and Reimbursement Issues
- Competition
- Future Prospects
Chapter 7: Sequencing Market Analysis
- Sequencing Market Overview
- Sequencing Market - Geographical Distribution
- Brand Ownership
- Sequencing Market - Research versus Clinical Use
- Sequencing Methods/Applications
- Clinical Sequencing Market - Disease Indications
- Analysis of Deals Activity in Next Generation Sequencing
Chapter 8: Company Profiles - Next Generation Sequencing Companies
- 10x Genomics, Inc.
- 23andMe, Inc.
- Abbott Laboratories
- ACT Genomics Co., Ltd.
- Adaptive Biotechnologies Corporation
- Admera Health
- Advanced Biological Laboratories (ABL), S.A
- Agilent Technologies Inc.
- AltheaDx, Inc.
- Ambry Genetics Corp.
- Aperiomics, Inc.
- Asuragen, Inc.
- Athena Diagnostics, Inc. (A Quest Diagnostics Business)
- Base4 Innovation Ltd
- Beckman Coulter, Inc. (Subsidiary of Danaher Corporation)
- Becton, Dickinson and Company (BD)
- BGI
- Bina Technologies, Inc. (Part of Roche Sequencing)
- BioDiscovery, Inc.
- Biomatters Ltd.
- bioMérieux SA
- bioTheranostics, Inc.
- Cancer Genetics, Inc.
- CareDx, Inc.
- Caris Life Sciences
- CLC bio (A QIAGEN Company)
- Color Genomics, Inc.
- Complete Genomics (A BGI Company)
- Courtagen Life Sciences, Inc.
- Cynvenio Biosystems, Inc.
- DNA Electronics Ltd.
- Eurofins Genomics
- Exosome Diagnostics, Inc.
- Foundation Medicine, Inc.
- GATC Biotech AG
- GenapSys, Inc.
- GenDx
- GENEWIZ Inc.
- Genia Technologies, Inc. (Part of Roche Sequencing)
- Genomic Health, Inc.
- Genoptix (A Novartis Company)
- GnuBIO, Inc. (A Bio-Rad Company)
- GRAIL
- Guardant Health, Inc.
- Helix
- HTG Molecular Diagnostics
- Human Longevity, Inc.
- Illumina, Inc.
- Inivata Ltd.
- Invitae Corporation
- Invivoscribe Technologies, Inc.
- Laboratory Corporation of America (LabCorp)
- Lasergen, Inc.
- MolecularMD Corporation
- Myriad Genetics, Inc.
- NANTOMICS (Member of the NantWorks ecosystem of companies)
- Natera, Inc.
- NeoGenomics, Inc./NeoGenomics Laboratories
- N-of-One, Inc.
- OncoDNA SA
- Oncospire Genomics
- Oxford Nanopore Technologies Ltd.
- Pacific Biosciences of California, Inc.
- Pathway Genomics Corporation
- Personal Genome Diagnostics, Inc.
- Personalis, Inc.
- QIAGEN N.V.
- Quest Diagnostics
- RainDance Technologies, Inc.
- Roche
- Siemens Healthcare Diagnostics
- Stratos Genomics Inc.
- Sysmex Corporation
- Thermo Fisher Scientific, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/l8tj43/next_generation
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Computing and Technology, Molecular Diagnostics


Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 



